Skip to main content

Fiscal Wizard · Single-issue tearsheet

DGX / Jun 21, 2026 Run #7517

DGX

Quest Diagnostics Incorporated

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Composite verdict

A 80.1 / 100
Bullish setup · Trend Following 15 drivers · 3 gates blocking
  • Double 7s
  • MA Rejection
  • Connors RSI(2)
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 2nd of 48 in Diagnostics & Research

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 25 signals0% Bear
Momentum Bullish 89Mean-reversion Neutral 58

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -62%
Asset value $64.77Earnings power value $76.09Price $195.00

Priced above its no-growth earnings power value ($76.09/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

60.3 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Inventory Turnover 100
Margin of Safety 0
Payout Ratio 96
OCF to Net Income 0
Cash Conversion Cycle 92
Earnings Yield 17

Technicals Bullish

100.0 / 100

Bullish setup leads (Double 7s, MA Rejection, Connors RSI(2)); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Double 7s 88
MA Rejection 88
Connors RSI(2) 86

Risk Gates

3 blocking 6 caution

3 guards active, 16 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for DGX.